DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30

BRIGHT MINDS BIOSCIENCES INC.

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 23, 2025

$53.82+2.52 (+4.91%)

Close on Oct 19, 2026

BRIGHT MINDS BIOSCIENCES INC. income statement

AnnualQuarterlyTTM

CAD USD

Millions of CAD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30	FY 2020 2020-09-30	FY 2019 2019-09-30
Research & Development	11	1.18	5.00	12	6.31	0.35	–
Selling & Marketing	0.43	0.04	0.12	0.55	0.85	0.01	–
Income Tax Expense	0	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-12	-2.80	-7.37	-15	-8.65	-0.48	–
EPS (Basic)(per share)	-1.78	-0.65	-1.98	-6.06	-4.82	-0.65	–
EPS (Diluted)(per share)	–	-0.65	-1.98	-6.06	-4.82	-0.65	–
Shares Outstanding (Basic, Weighted)(shares)	6.88	4.31	3.72	2.47	1.79	0.72	–
Shares Outstanding (Diluted, Weighted)(shares)	6.88	4.31	3.72	2.47	1.79	0.72	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 36.10
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3550.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.